Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment
Trilaciclib, a novel cyclin-dependent kinase 4/6 inhibitor, has demonstrated the ability to protect bone marrow from chemotherapy toxicity, improving patients' quality of life (QoL). This review describes the mechanism of action, efficacy, and toxicity profile of trilaciclib. Trilaciclib halts retin...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-08-01
|
| Serie: | Indian Journal of Medical and Paediatric Oncology |
| Soggetti: | |
| Accesso online: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1786017 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|